Fig 1.

Darbepoetin and epoetin use among South Carolina Medicaid-covered patients with chemotherapy-induced anemia and breast cancer, non–small-cell lung cancer, or colorectal cancer (2002 to 2010).^12-15 BEST, Breast Cancer Erythropoietin Survival Trial; CMS, Centers for Medicare and Medicaid Services; ENHANCE, Erythropoietin in Head and Neck Cancer Study; ESA, erythropoiesis-stimulating agent; FDA, US Food and Drug Administration; NCD, National Coverage Determination; VTE, venous thromboembolism.